Investors bought shares of Abbott Laboratories (NYSE:ABT) on weakness during trading on Thursday. $52.24 million flowed into the stock on the tick-up and $33.01 million flowed out of the stock on the tick-down, for a money net flow of $19.23 million into the stock. Of all companies tracked, Abbott Laboratories had the 22nd highest net in-flow for the day. Abbott Laboratories traded down ($0.32) for the day and closed at $44.36

Several research firms have recently commented on ABT. Bank of America Corp. restated a “buy” rating and set a $50.00 price target on shares of Abbott Laboratories in a research report on Friday, August 12th. BTIG Research restated a “buy” rating and set a $45.00 price target on shares of Abbott Laboratories in a research report on Wednesday, August 10th. Deutsche Bank AG restated a “buy” rating on shares of Abbott Laboratories in a research report on Tuesday, August 9th. Jefferies Group upped their price target on shares of Abbott Laboratories from $49.00 to $52.00 and gave the stock a “buy” rating in a research report on Thursday, August 4th. Finally, Argus restated a “buy” rating and set a $55.00 price target on shares of Abbott Laboratories in a research report on Thursday, July 28th. Eight research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $47.08.

The stock has a 50 day moving average price of $43.44 and a 200-day moving average price of $40.55. The company has a market capitalization of $65.03 billion and a price-to-earnings ratio of 29.20.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Wednesday, July 20th. The healthcare product maker reported $0.55 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.53 by $0.02. The business earned $5.30 billion during the quarter, compared to the consensus estimate of $5.24 billion. During the same period in the prior year, the firm earned $0.52 earnings per share. The business’s quarterly revenue was up 3.2% compared to the same quarter last year. On average, equities research analysts anticipate that Abbott Laboratories will post $2.20 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 15th. Investors of record on Friday, July 15th were given a $0.26 dividend. The ex-dividend date was Wednesday, July 13th. This represents a $1.04 dividend on an annualized basis and a yield of 2.35%.

In related news, EVP Hubert L. Allen sold 3,400 shares of Abbott Laboratories stock in a transaction dated Tuesday, June 28th. The stock was sold at an average price of $37.14, for a total value of $126,276.00. Following the completion of the sale, the executive vice president now directly owns 91,857 shares in the company, valued at $3,411,568.98. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Stephen R. Fussell sold 41,500 shares of Abbott Laboratories stock in a transaction dated Thursday, July 28th. The stock was sold at an average price of $45.00, for a total value of $1,867,500.00. Following the completion of the sale, the insider now owns 196,467 shares of the company’s stock, valued at $8,841,015. The disclosure for this sale can be found here.

Other institutional investors recently bought and sold shares of the company. Diamond Hill Capital Management Inc. raised its position in Abbott Laboratories by 2.8% in the fourth quarter. Diamond Hill Capital Management Inc. now owns 8,621,765 shares of the healthcare product maker’s stock valued at $387,203,000 after buying an additional 236,352 shares during the last quarter. RBO & Co. LLC bought a new position in Abbott Laboratories during the fourth quarter valued at about $7,558,000. US Bancorp DE raised its position in Abbott Laboratories by 5.3% in the fourth quarter. US Bancorp DE now owns 3,115,593 shares of the healthcare product maker’s stock valued at $139,921,000 after buying an additional 157,639 shares during the last quarter. Cambridge Investment Research Advisors Inc. bought a new position in Abbott Laboratories during the fourth quarter valued at about $5,419,000. Finally, Schwab Charles Investment Management Inc. raised its position in Abbott Laboratories by 2.6% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 4,503,068 shares of the healthcare product maker’s stock valued at $202,233,000 after buying an additional 115,706 shares during the last quarter.

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.